Logo image of BDSX

BIODESIX INC (BDSX) Stock Fundamental Analysis

USA - NASDAQ:BDSX - US09075X1081 - Common Stock

6.65 USD
-0.08 (-1.19%)
Last: 10/27/2025, 4:14:04 PM
6.66 USD
+0.01 (+0.15%)
After Hours: 10/27/2025, 4:14:04 PM
Fundamental Rating

2

Taking everything into account, BDSX scores 2 out of 10 in our fundamental rating. BDSX was compared to 101 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of BDSX have multiple concerns. BDSX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BDSX has reported negative net income.
In the past year BDSX has reported a negative cash flow from operations.
In the past 5 years BDSX always reported negative net income.
BDSX had a negative operating cash flow in each of the past 5 years.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -46.82%, BDSX is not doing good in the industry: 90.10% of the companies in the same industry are doing better.
BDSX's Return On Equity of -3609.67% is on the low side compared to the rest of the industry. BDSX is outperformed by 84.16% of its industry peers.
Industry RankSector Rank
ROA -46.82%
ROE -3609.67%
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

With an excellent Gross Margin value of 78.77%, BDSX belongs to the best of the industry, outperforming 93.07% of the companies in the same industry.
In the last couple of years the Gross Margin of BDSX has remained more or less at the same level.
BDSX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BDSX has been increased compared to 1 year ago.
Compared to 5 years ago, BDSX has more shares outstanding
The debt/assets ratio for BDSX is higher compared to a year ago.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.56, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
BDSX has a Altman-Z score of -7.56. This is amonst the worse of the industry: BDSX underperforms 91.09% of its industry peers.
BDSX has a Debt/Equity ratio of 41.11. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BDSX (41.11) is worse than 85.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 41.11
Debt/FCF N/A
Altman-Z -7.56
ROIC/WACCN/A
WACC13.55%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 2.14 indicates that BDSX has no problem at all paying its short term obligations.
BDSX has a better Current ratio (2.14) than 77.23% of its industry peers.
BDSX has a Quick Ratio of 2.14. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.14, BDSX is in the better half of the industry, outperforming 78.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 2.14
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BDSX have decreased strongly by -623.91% in the last year.
Looking at the last year, BDSX shows a very strong growth in Revenue. The Revenue has grown by 25.71%.
BDSX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.78% yearly.
EPS 1Y (TTM)-623.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
Revenue 1Y (TTM)25.71%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%11.68%

3.2 Future

Based on estimates for the next years, BDSX will show a very negative growth in Earnings Per Share. The EPS will decrease by -82.92% on average per year.
The Revenue is expected to grow by 21.80% on average over the next years. This is a very strong growth
EPS Next Y-1473.71%
EPS Next 2Y-218.46%
EPS Next 3Y-82.92%
EPS Next 5YN/A
Revenue Next Year17.43%
Revenue Next 2Y21.84%
Revenue Next 3Y21.8%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BDSX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDSX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as BDSX's earnings are expected to decrease with -82.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-218.46%
EPS Next 3Y-82.92%

More info and screens

0

5. Dividend

5.1 Amount

BDSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODESIX INC

NASDAQ:BDSX (10/27/2025, 4:14:04 PM)

After market: 6.66 +0.01 (+0.15%)

6.65

-0.08 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners22.98%
Inst Owner Change0%
Ins Owners25.97%
Ins Owner Change1.54%
Market Cap48.74M
Revenue(TTM)76.56M
Net Income(TTM)-41078000
Analysts80
Price Target35.7 (436.84%)
Short Float %N/A
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.06%
Min EPS beat(2)-15.34%
Max EPS beat(2)-14.78%
EPS beat(4)2
Avg EPS beat(4)-2.99%
Min EPS beat(4)-15.34%
Max EPS beat(4)11.77%
EPS beat(8)6
Avg EPS beat(8)3.3%
EPS beat(12)8
Avg EPS beat(12)1.74%
EPS beat(16)11
Avg EPS beat(16)2.05%
Revenue beat(2)1
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-9.55%
Max Revenue beat(2)6.29%
Revenue beat(4)2
Avg Revenue beat(4)-1.73%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)6.29%
Revenue beat(8)4
Avg Revenue beat(8)-1.48%
Revenue beat(12)6
Avg Revenue beat(12)-1.3%
Revenue beat(16)8
Avg Revenue beat(16)0.19%
PT rev (1m)1900%
PT rev (3m)1844.44%
EPS NQ rev (1m)-1758.06%
EPS NQ rev (3m)-2300%
EPS NY rev (1m)4.42%
EPS NY rev (3m)-2119.21%
Revenue NQ rev (1m)0.71%
Revenue NQ rev (3m)0.73%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)1.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.64
P/FCF N/A
P/OCF N/A
P/B 42.83
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.33
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-4.28
FCFYN/A
OCF(TTM)-4.08
OCFYN/A
SpS10.44
BVpS0.16
TBVpS-2.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.82%
ROE -3609.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.77%
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
F-Score3
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 41.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.1%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 2.14
Altman-Z -7.56
F-Score3
WACC13.55%
ROIC/WACCN/A
Cap/Depr(3y)283.54%
Cap/Depr(5y)201.2%
Cap/Sales(3y)20.35%
Cap/Sales(5y)14.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-623.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
EPS Next Y-1473.71%
EPS Next 2Y-218.46%
EPS Next 3Y-82.92%
EPS Next 5YN/A
Revenue 1Y (TTM)25.71%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%11.68%
Revenue Next Year17.43%
Revenue Next 2Y21.84%
Revenue Next 3Y21.8%
Revenue Next 5YN/A
EBIT growth 1Y-2.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.14%
EBIT Next 3Y31.94%
EBIT Next 5YN/A
FCF growth 1Y31.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.12%
OCF growth 3YN/A
OCF growth 5YN/A

BIODESIX INC / BDSX FAQ

Can you provide the ChartMill fundamental rating for BIODESIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to BDSX.


Can you provide the valuation status for BIODESIX INC?

ChartMill assigns a valuation rating of 0 / 10 to BIODESIX INC (BDSX). This can be considered as Overvalued.


Can you provide the profitability details for BIODESIX INC?

BIODESIX INC (BDSX) has a profitability rating of 1 / 10.


Can you provide the financial health for BDSX stock?

The financial health rating of BIODESIX INC (BDSX) is 3 / 10.


What is the expected EPS growth for BIODESIX INC (BDSX) stock?

The Earnings per Share (EPS) of BIODESIX INC (BDSX) is expected to decline by -1473.71% in the next year.